What Biocrates Life Sciences does

Biocrates Life Sciences is an Austria-based life sciences company that develops and sells standardized, mass spectrometry-based targeted metabolomics kits, software, and services for pharmaceutical, academic, and clinical research customers. Founded in 2002 and headquartered in Innsbruck with a US sales entity in Aliso Viejo, California, the company built a portfolio of nine targeted profiling kits (including the MxP Quant 1000, MxP Quant 500 XL, AbsoluteIDQ p180, and AbsoluteIDQ Bile Acids) and three proprietary software products (WebIDQ workflow manager, MetaboINDICATOR, and the Quantitative Metabolomics Database), all anchored by a patented 96-well filter plate kit format validated across the four major LC-MS instrument vendors. Its commercial model combines one-time kit and consumable sales, recurring WebIDQ/QMDB software subscriptions (cloud and on-premises), and fee-for-service metabolomics phenotyping and biostatistics, distributed through a direct webshop, field sales, regional distribution partners, and a network of more than 100 certified partner laboratories worldwide.

In June 2025, Biocrates was acquired by Bruker Corporation to strengthen Bruker's multiomics capabilities, and was subsequently integrated into the Biognosys Group to align its metabolomics offerings with Biognosys' proteomics franchise. The company sells primarily into pharmaceutical and biotech drug-discovery programs, academic and epidemiological research, and clinical/translational studies, with cited users including Biogen, Heidelberg University and the German Cancer Research Center, Baylor Scott & White Research Institute, and Fraunhofer ITEM.

Name

Biocrates Life Sciences

Legal name

biocrates life sciences gmbh

Website

https://biocrates.com

Company type

Private

Founded year

2002

Operating status

Acquired

Headcount range

11–50 employees

Short description

Biocrates Life Sciences develops standardized mass spectrometry-based metabolomics kits, software, and services for pharmaceutical, academic, and clinical research customers; its targeted kits and WebIDQ/QMDB platform serve drug discovery, epidemiology, and translational research globally.

Ownership category

akta.pro rank

Product category

Life Sciences Research Tools — Metabolomics

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714), Medical Laboratories (621511), In-Vitro Diagnostic Substance Manufacturing (325413)

SIC

Services-Commercial Physical & Biological Research (8731), Services-Medical Laboratories (8071), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Metabolomics & Lipidomics Services (HLAGANAG)

akta.pro secondary industries

Bioanalytical & Biomarker Assays (Preclinical) (HLAGAFAK), Microbiome & Metagenomics Services (HLAGANAH), Mass Spectrometry & Spectroscopy Instruments (HLAGAIAB)

Keywords

• Targeted metabolomics kits
• Mass spectrometry reagents
• Quantitative metabolomics services
• Lipidomics profiling kits
• Multiomics data analysis

Headquarters

HQ city

Innsbruck

HQ country

Austria

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Operations, Marketing or Sales

Revenue model

1. Metabolomics Kit Products: Sale of mass spectrometry-based metabolomics kits including MxP Quant 1000, MxP Quant 500 XL, MxP Quant 500, MxP Quant HR Xpress, AbsoluteIDQ p400 HR, AbsoluteIDQ p180, AbsoluteIDQ Bile Acids, and SMartIDQ alpha kits. Kits are available in various sizes (full kit 80 samples, half kit 40 samples, starter kit 10 samples) and configurations for UHPLC and HPLC systems.
2. Software Subscriptions (WebIDQ): WebIDQ workflow management software available as cloud-based or on-premises subscription. Cloud subscription includes automatic updates and database management. On-premises subscription requires local server setup. Subscription includes concurrent user access based on plan tier.
3. QMDB Subscription: Quantitative metabolomics database subscription providing access to reference metabolite ranges for data interpretation and validation.
4. Metabolomics Services: Expert services including metabolomics phenotyping, data analysis and biostatistics, pathway analysis, multiomics data analysis, expert data consulting, and data interpretation services performed by in-house experts.
5. Accessories and Consumables: Kit-specific columns, precolumns, urine extension, and additional support hours.

Pricing tiers

Go-to-market motion1 record

Distribution channels5 records

Marketing channels8 records

Core offering

Biocrates Life Sciences develops and commercializes mass spectrometry-based targeted metabolomics kits (MxP Quant and AbsoluteIDQ product families) along with proprietary software (WebIDQ, MetaboINDICATOR) and a quantitative metabolomics database (QMDB). The company also offers metabolomics phenotyping services, biostatistics and multiomics data analysis for pharmaceutical, academic, and clinical research customers.

Product overview

Biocrates Life Sciences offers a comprehensive targeted metabolomics portfolio centered on quantitative, standardized kit technology and proprietary software. The core offering consists of nine targeted profiling kits (MxP Quant 1000, LxQuant, MxQuant, MxP Quant 500 XL, MxP Quant 500, MxP Quant HR Xpress, SMartIDQ alpha kit, AbsoluteIDQ p400 HR, AbsoluteIDQ p180) and one pathway-specific kit (AbsoluteIDQ Bile Acids) designed for mass spectrometry-based quantitative metabolomics and lipidomics. These kits are supported by three proprietary software products: WebIDQ (cloud/on-premises workflow manager), MetaboINDICATOR (metabolism indicators), and QMDB (Quantitative Metabolomics Database with global reference ranges). Services include metabolomics phenotyping, data analysis/biostatistics, pathway analysis, and multiomics data analysis. The portfolio is complemented by THE STORY principle, a published guide for biological interpretation of metabolomics. The company also offers certified laboratory partner networks for customers without LC-MS access.

Differentiator

Problem solved

Functional benefit

Brands

• MxP: Product line of targeted profiling kits including MxP Quant 1000, MxP Quant 500, MxP Quant 500 XL, MxP Quant HR Xpress, and MxQuant kits for comprehensive metabolomics profiling.
• AbsoluteIDQ
• WebIDQ
• MetaboINDICATOR
• QMDB
• SMartIDQ

Products and services

• MxP Quant 1000 kit

Quantifiable outcome

• Eliminates variability and generates reproducible data across studies
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature7 records

Partnerships

Five partnerships are on record, tiered core and minor.

• BiognosyscoreStrategic or Co-development Partner · 12 June 2026Biocrates is now part of the Biognosys Group following the Bruker acquisition. Biognosys specializes in proteomics solutions including Spectronaut and SpectroMine software. Biocrates' metabolomics capabilities complement Biognosys' proteomics offerings for multiomics research. The companies co-present at conferences and share scientific resources.
• SISCAPA Assay TechnologiescoreStrategic or Co-development PartnerBiognosys formed a collaboration with SISCAPA Assay Technologies to develop ultra-sensitive targeted protein assays for clinical research. This partnership aims to combine Biognosys' proteomics expertise with SISCAPA's assay technology for enhanced clinical research applications.
• Bruker CorporationcoreStrategic or Co-development PartnerPartnership expanded through hybrid metabolomics offerings developed through collaboration between Bruker and Biocrates. At ASMS 2026, Biognosys (with Biocrates) demonstrated optimized workflows and expanded metabolomics capabilities in partnership with Bruker.
• Global Distribution PartnersminorChannel Partner/ Reseller/ DistributorBiocrates maintains a network of distribution partners for regional kit product distribution in various geographic markets worldwide.
• Certified Partner Laboratories (100+)coreChannel Partner/ Reseller/ DistributorGlobal network of over 100 certified laboratories and CROs authorized to run biocrates kits for customers without compatible LC-MS instrumentation, enabling standardized service delivery worldwide.

Scale indicators5 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Metabolon: Metabolon is the largest commercial metabolomics services company offering untargeted and targeted metabolite profiling using mass spectrometry, directly competing with Biocrates in pharma and academic markets. Both serve drug discovery, clinical research, and population studies with quantitative metabolomics.
• Human Metabolome Technologies: Human Metabolome Technologies (HMT) is a Japan-based metabolomics company providing targeted CE-MS and LC-MS metabolite profiling services and kits, competing directly with Biocrates in targeted metabolomics for pharma and academic research globally.
• Biognosys: Biognosys is now the parent group of Biocrates following Bruker's acquisition, offering proteomics software (Spectronaut, SpectroMine) and DIA workflows. Sister company rather than direct competitor, but the two jointly pursue multiomics offerings as part of the Biognosys Group.

Broad incumbents

• Bruker Corporation: Bruker is Biocrates' parent company and a major life science instruments provider offering mass spectrometry, NMR, and proteomics platforms. Comparable as a broad incumbent in analytical life sciences whose strategy now incorporates Biocrates' metabolomics kits.
• Thermo Fisher Scientific: Thermo Fisher is a leading LC-MS instrument manufacturer whose mass spectrometry platforms are validated for use with Biocrates kits. It also offers its own metabolomics solutions and services, making it both a critical enabler and a broad incumbent competitor.
• SCIEX: SCIEX (a Danaher operating company) is a major provider of mass spectrometry systems validated for Biocrates kits. It offers its own metabolomics and quantitative workflows, positioning it as a broad incumbent that can both enable and compete with Biocrates' kit business.
• Waters Corporation: Waters is a leading LC-MS instrument manufacturer whose ACQUITY and Xevo systems are validated for Biocrates kits. As a broad life-sciences incumbent, Waters both enables Biocrates' customers and competes in metabolomics applications via its own informatics offerings.
• Agilent Technologies: Agilent provides LC-MS instrumentation validated for use with Biocrates kits and operates its own metabolomics services and bioinformatics offerings, making it a broad incumbent that overlaps with Biocrates across instruments and downstream analysis.

Emerging players

• Olink Holding: Olink provides high-plex targeted proteomics using PEA technology for biomarker discovery in pharma and clinical research. It is an adjacent emerging player in the multiomics space where Biocrates competes for translational research budget.

Regional players

• Creative Proteomics: Creative Proteomics is a US-based CRO offering metabolomics, proteomics, and lipidomics services using LC-MS, including Biocrates-style targeted panels. It is a regional services competitor overlapping with Biocrates' certified lab network use cases.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xx.com/biocrates_
• YouTubeyoutube.com/c/biocrateslifesciences
• LinkedInlinkedin.com/company/biocrates

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds8 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Biocrates Life Sciences